|
(n = 210) |
(n = 194) |
|
Log [folliculin level] (pg/mL)* |
4.4 ± 0.3 |
5.2 ± 0.4 |
< 0.001 |
Age (mean ± SD, years) |
48.8 ± 14.2 (n = 206) |
53.1 ± 14.7 (n = 188) |
0.003 |
Sex (n, % male) |
42.72 (n = 88) |
46.81 (n = 88) |
0.475 |
BMI (kg/m2) |
23.7 ± 3.3 (n = 202) |
23.8 ± 3.0 (n =
187) |
0.688 |
Age of diagnosis (year) |
43.8 ± 15.7 (n = 196) |
46.1 ± 17.5 (n = 177) |
0.091 |
Age of symptom onset (year) |
38.6 ± 16.3 (n = 202) |
42.7 ± 17.6 (n =
185) |
0.018 |
Smoking (pack-years) |
7.2 ± 13.3 (n = 197) |
10.6 ± 18.0 (n = 182) |
0.043 |
Smoker a) (%) |
45.7 (n = 90) |
49.5 (n = 90) |
0.528 |
Smoking status (%) |
|
|
0.615 |
Never-smoker
|
54.3 (n = 107)
|
50.6 (n = 92)
|
|
Ex-smoker
|
31.5 (n = 62)
|
36.3 (n = 66)
|
|
Current smoker
|
14.2 (n = 28)
|
13.2 (n = 24)
|
|
Skin prick test (% positive, n/total) |
42.4 (n = 64) |
34.5 (n = 39) |
0.242 |
Acute exacerbation, past 1 year (yes, %) |
17.5 (n = 36) |
13.8 (n =
26) |
0.393 |
Acute exacerbation (/1 year) |
3.3 ± 5.0 (n = 53) |
4.4 ± 8.3 (n = 70) |
0.349 |
Pre-BD FEV1(%) |
73.5 ± 19.8 (n = 201) |
69.1 ± 22.8 (n = 183) |
0.045 |
Pre-BD FVC (%) |
88.5 ± 18.6 (n = 201) |
84.3 ± 18.4 (n = 183) |
0.026 |
Pre-BD FEV1/FVC |
0.69 ± 0.13 (n = 202) |
0.67 ± 0.16 (n = 184) |
0.098 |
Post-BD FEV1 predicted (%) |
76.3 ± 21.4 (n = 98) |
70.0 ± 22.0 (n =
117) |
0.034 |
Post-BD FVC predicted (%) |
89.4 ± 18.2 (n = 98) |
83.6 ± 17.4 (n =
117) |
0.018 |
Post-BD FEV1/FVC predicted |
0.69 ± 0.13 (n = 98) |
0.67 ± 0.19 (n =
117) |
0.507 |
PC20 |
4.5 ± 5.0 (n = 89) |
5.6 ± 6.3 (n = 59) |
0.260 |
Blood eosinophils (%) |
5.6 ± 5.6 (n = 177) |
4.7 ± 4.8 (n = 148) |
0.131 |
Blood eosinophil count (cells) |
396.6 ± 445.0 (n = 177) |
336.2 ± 334.9
(n = 148) |
0.164 |
Neutrophils (%), sputum |
44.7 ± 37.7 (n = 24) |
39.0 ± 34.5 (n = 29) |
0.557 |
Eosinophils (%), sputum |
18.9 ± 27.0 (n = 24) |
14.4 ± 24.3 (n = 29) |
0.495 |
CRP (mg/dL) |
0.6 ± 1.4 (n = 111) |
0.6 ± 1.6 (n = 104) |
0.902 |
Serum total IgE (IU/mL) |
362.5 ± 490.6 (n = 60) |
589.5 ± 1034.1 (n =
53) |
0.161 |